V2P

V2P is an experimental **PEGylated netrin-1-derived small peptide** developed in academic preclinical research as a potential therapy for **pulmonary hypertension**. It is derived from the native netrin-1 peptide V2, which corresponds to amino acids 368-377 of human netrin-1 with sequence **CLNCRHNTAG**, and was chemically modified by **polyethylene glycol conjugation** to improve stability and cell permeability. In a hypoxia-induced mouse model of pulmonary hypertension, V2P reduced mean pulmonary arterial pressure, right ventricular systolic pressure, right heart hypertrophy, pulmonary vascular remodeling, fibrosis, oxidative stress, and mitochondrial superoxide, while restoring nitric oxide bioavailability and reversing eNOS uncoupling. The mechanistic rationale described for V2P is engagement of the **Deleted in Colorectal Carcinoma receptor** signaling axis, leading to preservation of coupled endothelial nitric oxide synthase activity, increased nitric oxide signaling, and suppression of oxidative stress pathways. The program appears to remain **preclinical** and is associated with research led by investigators at UCLA rather than a commercial development-stage drug company.

Other names

PEGylated V2 peptidenetrin-1-derived modified peptide V2Pnetrin1-derived modified peptide V2Pnetrin 1-derived modified peptide V2P